Paul Ruddock

Pioneering Quantum Computing in the Energy Industry: Chevron Joins OQC's $100 Million Round

Retrieved on: 
Tuesday, March 5, 2024
Engineering, Innovation, Paul Ruddock, University, News, Quantum, Transport, OIC, Growth, Carbon, Physics, UTEC, Chevron Corporation, CVX, Microscope

Chevron's investment marks a significant move by a supermajor into the rapidly evolving field of quantum computing.

Key Points: 
  • Chevron's investment marks a significant move by a supermajor into the rapidly evolving field of quantum computing.
  • The company aims to make it possible to offer hybrid computing, integrated quantum and high-performance computing, to the market.
  • To realise this future, the energy industry requires secure, accessible and powerful quantum computing that is integrated with existing high-performance computing.
  • We're excited to drive innovation and efficiency in exploration and renewables and pioneer enterprise-ready quantum in the energy sector."

TechMet Receives further $50 Million Commitment From U.S. International Development Finance Corporation at COP28

Retrieved on: 
Friday, December 1, 2023
Environment, EV, Electric Vehicles, Climate Change, Automotive, Chemicals, Plastics, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Lithium, Momentum, Brian Menell, Climate change, Metal, UK Infrastructure Bank, COP28, Recycling, EVS, Exercise, Mineral group, DFC, Conference, Phalaborwa, One Atlantic Center, Letter, Rainbow, Paul Ruddock, Cornish Lithium, Cryptocurrency, Security (finance), Renewable energy, Rare-earth element, Uranium mining, Green Zone

TechMet , a global critical minerals investment company, has secured a further $50 million commitment from the U.S. International Development Finance Corporation (DFC) as part of its latest fundraising round.

Key Points: 
  • TechMet , a global critical minerals investment company, has secured a further $50 million commitment from the U.S. International Development Finance Corporation (DFC) as part of its latest fundraising round.
  • The additional commitment from the U.S. Government’s development finance institution comes as TechMet opens a new $300 million equity funding round.
  • DFC is already a key shareholder in TechMet and this will raise its total investment to $105 million, following an initial investment in 2020.
  • TechMet, founded in 2017, is an investment company focused on building businesses across the critical metals value chain, from extraction and processing to recycling and supply-chain management.

OQC launches OQC Toshiko, the world's first enterprise ready quantum platform

Retrieved on: 
Monday, November 27, 2023
Quantum, GPU, Climate change, Chemistry, Government, Algorithm, Toshiko, UTEC, Machine learning, Series, University, Drug discovery, Oxford Sciences Enterprises, HPC, OSE, Partnership, Qinetiq, SBI Group, Growth, Equinix, Female, McKinsey & Company, News, AWS, OIC, Paul Ruddock, Renewable energy, Mobile phone, Fine chemical, Cryptocurrency, Financial services, NVIDIA

LONDON, Nov. 27, 2023 /PRNewswire/ -- OQC, the global leaders in quantum compute-as-a-service (QCaaS), today announced the public availability of OQC Toshiko, the world's first enterprise ready quantum computing platform, and that SBI Investment, Japan's premier VC fund, is leading OQC's $100m round.

Key Points: 
  • OQC's $100m round will pave the way for industry-leading R&D furthering its ability to bring enterprise ready quantum to businesses globally.
  • With OQC Toshiko, an upgradeable 32-qubit platform, OQC has brought quantum computing to commercial data centres, thereby enabling secure and easy access for customers.
  • Bringing quantum into data centres makes it possible to offer hybrid compute, integrated quantum and HPC, to the market.
  • To bring quantum out of the lab and into the enterprise, OQC is collaborating with leading global companies including Equinix, NVIDIA, AWS and McKinsey.

OQC launches OQC Toshiko, the world's first enterprise ready quantum platform

Retrieved on: 
Monday, November 27, 2023
Quantum, GPU, Climate change, Chemistry, Government, Algorithm, Toshiko, UTEC, Machine learning, Series, University, Drug discovery, Oxford Sciences Enterprises, HPC, OSE, Partnership, Qinetiq, SBI Group, Growth, Equinix, Female, McKinsey & Company, News, AWS, OIC, Paul Ruddock, Renewable energy, Mobile phone, Fine chemical, Cryptocurrency, Financial services, NVIDIA

LONDON, Nov. 27, 2023 /PRNewswire/ -- OQC, the global leaders in quantum compute-as-a-service (QCaaS), today announced the public availability of OQC Toshiko, the world's first enterprise ready quantum computing platform, and that SBI Investment, Japan's premier VC fund, is leading OQC's $100m round.

Key Points: 
  • OQC's $100m round will pave the way for industry-leading R&D furthering its ability to bring enterprise ready quantum to businesses globally.
  • With OQC Toshiko, an upgradeable 32-qubit platform, OQC has brought quantum computing to commercial data centres, thereby enabling secure and easy access for customers.
  • Bringing quantum into data centres makes it possible to offer hybrid compute, integrated quantum and HPC, to the market.
  • To bring quantum out of the lab and into the enterprise, OQC is collaborating with leading global companies including Equinix, NVIDIA, AWS and McKinsey.

TechMet closes $200m equity raise to further develop critical minerals operations

Retrieved on: 
Tuesday, August 15, 2023
Momentum, Michael Mullen, DLE, UK Infrastructure Bank, EV, Metal, Face, Nickel, Brian Menell, Energy, Recycling, Cornish Lithium, Mineral group, Paul Ruddock, EVS, DFC, Climate change, Tungsten, Mining, Mercuria, Tin, Legislation, Cryptocurrency, Pharmaceutical industry, Renewable energy, Rare-earth element, Management, Lithium, EU, Q4

TechMet, the global critical minerals investment company backed by the US Development Finance Corporation, closes $200 million fundraising round.

Key Points: 
  • TechMet, the global critical minerals investment company backed by the US Development Finance Corporation, closes $200 million fundraising round.
  • In the last 12 months, TechMet has invested more than $180 million into critical minerals projects around the world.
  • WASHINGTON and LONDON and DUBLIN, Ireland, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TechMet , the leading global critical minerals investment company, has closed its latest $200 million equity fundraising round.
  • Menell added: “Recent US legislation supporting the critical minerals sector, and supply chain investments by major automakers, represent significant steps forward.

Replay receives $1.5 million grant for its hypoimmunogenic technology platform

Retrieved on: 
Monday, November 28, 2022
Sir, Skin, KKR, IPS, University, DNA, Brain, Regenerative medicine, Bill, Patient, Potency (pharmacology), IPSC, Protein engineering, Induce, Genome, HSV, Pathology, Neurodegeneration, Infection, Cancer, Paul Ruddock, Writing, Stem cell genomics, Synthetic biology, Sir William Dunn School of Pathology, Bill & Melinda Gates Foundation, AAV, Biology, Eye, Pharmaceutical industry, Vaccine, Replay

Replays uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.

Key Points: 
  • Replays uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.
  • The technology is relevant to both the developed and developing worlds, with the anticipated reduced cost-of-goods improving equity of access.
  • Lachlan MacKinnon, Chief Executive Officer, and Co-Founder of Replay, added: Replays hypoimmunogenic technology is the result of a convergence of synthetic biology, computational design, and protein engineering with iPS cell technology.
  • The Companys hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms.

Osler Diagnostics Raises $85 Million in Series C Financing

Retrieved on: 
Monday, November 7, 2022
University, Company, Research, Paul Ruddock, Investment, CEO, Adoption, Entrepreneurship, M&G, Health, Osler, Solution, Financial services, Medical imaging

Oxford, UK 7th November 2022:

Key Points: 
  • Oxford, UK 7th November 2022:
    Osler Diagnostics (Osler), a medical diagnostic company aiming to transform global healthcare by providing lab-quality diagnostic testing to anyone, anywhere, at any time, today announced that it has raised $85 million in a Series C financing.
  • This investment will support Osler in advancing its breakthrough Osler Origin product through regulatory activities, and towards market launch.
  • Connor Campbell, Co-Founder and CEO of Osler Diagnostics, said: The Osler Origin platform has the potential to transform healthcare by enabling anyone, anywhere, to access, understand, and act on their healthcare information.
  • Osler has developed the Osler Origin a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time.

DeciBio Ventures Invests in Replay’s $55M seed funding round led by KKR & Co. and OMX Ventures

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Consulting, Health, Professional Services, Small Business, CA, DNA, KKR, Brain, Strategic planning, Investment, Skin, Eye, Harvard University, MIT, SALT, Genome, Industry, OSI, HSV, CEO, IP, Board, Therapy, Sangamo Therapeutics, Paul Ruddock, Virology, Adoption, EVP, Pfizer, Technology, Library, Precision medicine, Bristol Myers Squibb, ONI, Software as a service, VC, Synthetic biology, AAV, Financial services, Pharmaceutical industry, Replay, Axial

DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, invested in the seed funding round for Replay.

Key Points: 
  • DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, invested in the seed funding round for Replay.
  • KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.
  • As part of DeciBio Ventures strategy-heavy and supportive VC model, DeciBio Ventures is also providing Replay with ongoing strategic support.
  • Beyond Replays advanced technologies, DeciBio Ventures was drawn to Replays uniquely seasoned management team, founders, and Board members.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.

Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA

Retrieved on: 
Monday, July 25, 2022
MIT, Genome, MMS, Gene, Retirement, Sangamo Therapeutics, Late, Biological engineering, Pfizer, Company, LinkedIn, Biology, Professor, Brain, Investment, Skin, Eye, OSI, KKR, Doctor of Philosophy, Independent Board for Presbyterian Foreign Missions, Adverum Biotechnologies, Biotechnology, Technology, Library, Life, Growth, AAV, DNA, Insurance, SALT, Industry, Twitter, Neuroscience, CEO, Board, OMX, ONI, Therapy, Synthetic biology, Medicine, Science Publishing Group, CA, Massachusetts Institute of Technology, University, HSV, NYSE, Paul Ruddock, University of California, Berkeley, Stanford School, Senior advisor, Bristol Myers Squibb, Writing, Vaccine, Management, Cryptocurrency, Pharmaceutical industry, Fine chemical, Financial services, Microbiology, Research, Replay, Axial, Ophthalmology, MD

Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.

Key Points: 
  • Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: Genomic medicine has the potential to transform the future of clinical therapeutics.
  • Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.
  • Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
  • The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality.